2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 243

Relationship of Physical Activity with Health Utility in the Osteoarthritis Initiative
Abstract Number: 1588

Relationship Over Time Between Beliefs, Motivation, and Worries about Physical Activity and Physical Activity Participation in Persons with Knee Osteoarthritis
Abstract Number: 72

Relationships Between Air Pollution and Presence of Rheumatoid Arthritis-Related Autoantibodies in Individuals without Rheumatoid Arthritis: Studies of the Etiology of Rheumatoid Arthritis
Abstract Number: 585

Relative Overexpression of Membrane-Bound Versus Soluble TNF in Human and Experimental Spondyloarthritis
Abstract Number: 170

Relative Risk of Infusion Reactions with KRYSTEXXA® (pegloticase) From Post-Approval Safety Data: Results From Sept 2010 to June 2012
Abstract Number: 2100

Relative, Reliability-Adjusted Diagnostic Test Accuracy of Erosion Detection Between Magnetic Resonance Imaging and Radiography in Rheumatoid Arthritis
Abstract Number: 1033

Reliability and Responsiveness of Two Methods for Assessment of Magnetic Resonance Imaging Abnormalities in Hip Osteoarthritis in a Placebo-Controlled Trial of Intra-Articular Steroid Injection
Abstract Number: 124

Reliability of an Ultrasound Scoring Measure for Juvenile Localized Scleroderma (jLS)
Abstract Number: 2103

Reliability of DAS28 in Rheumatoid Arthritis When Based On Patient Self-Assessment of Tender and Swollen Joints
Abstract Number: 2029

Reliability of Scoring a Disease Damage Measure for Juvenile Localized Scleroderma
Abstract Number: 1018

Reliability of the Early Erosions in Rheumatoid Arthritis Software When Quantifying Bone Loss
Abstract Number: 394

Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis
Abstract Number: 1335

Remission Induction in Early Active Rheumatoid Arthritis: Comparison of Tocilizumab Versus Methotrexate Monotherapy
Abstract Number: 404

Remission is a Difficult Target in Clinical Practice When RA Disease Is Established
Abstract Number: 773

Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].